Sherry Chou, MD, University of Pittsburgh School of Medicine, Pittsburgh, PA, discusses the establishment and early findings of the Global Consortium to Study Neurological dysfunction in COVID-19 (GCS-NeuroCOVID; NCT04496128). The consortium was set up in March 2020 to gain valuable data needed to understand the prevalence, pathophysiology, and prognostic implications of neurological complications of SARS-CoV-2 infection. In a global collaborative effort, findings from The EAN Neuro-COVID Registry Consortium (ENERGY) were included in the first GCS-NeuroCOVID analysis, giving data from over 3000 patients from hundreds of registered sites across the world. Major findings included the observation of a high prevalence of neurological manifestations, affecting around 50% of patients hospitalized with COVID-19. Encephalopathy was the most common neurological syndrome and its occurrence, as well as the occurrence of any neurological syndrome, significantly increased the risk of death. This interview took place during the American Academy of Neurology (AAN) 2021 Annual Meeting.
